- Home
- Publications
- Publication Search
- Publication Details
Title
IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-03-29
DOI
10.3389/fonc.2021.639387
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
- (2020) Nicholas J. Short et al. Cancer Discovery
- Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. Food and Drug Administration systematic analysis
- (2020) Kelly J. Norsworthy et al. CLINICAL CANCER RESEARCH
- Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.
- (2020) Curtis Andrew Lachowiez et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).
- (2020) Courtney Denton Dinardo et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
- (2020) Sung Choe et al. Blood Advances
- Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. JOURNAL OF CLINICAL ONCOLOGY
- Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview
- (2020) Alessandro Barbato et al. Frontiers in Oncology
- FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation
- (2019) Kelly J. Norsworthy et al. CLINICAL CANCER RESEARCH
- Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
- (2019) Daniel A. Pollyea et al. LEUKEMIA
- Metabolic dependencies and vulnerabilities in leukemia
- (2019) Marissa Rashkovan et al. GENES & DEVELOPMENT
- Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
- (2019) Gail J. Roboz et al. BLOOD
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
- (2018) Gerrit J. Schuurhuis et al. BLOOD
- Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
- (2018) Lynn Quek et al. NATURE MEDICINE
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Wild-type and mutated IDH1/2 enzymes and therapy responses
- (2018) Remco J. Molenaar et al. ONCOGENE
- Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
- (2018) Janeta Popovici-Muller et al. ACS Medicinal Chemistry Letters
- Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2
- (2018) Amir T. Fathi et al. JAMA Oncology
- Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations
- (2018) Michael Buege et al. Cancers
- Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
- (2018) Andrew M. Intlekofer et al. NATURE
- Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
- (2018) Eytan M. Stein et al. BLOOD
- Enasidenib-induced eosinophilic differentiation in a patient with acute myeloid leukaemia with IDH2 and U2AF1 mutations
- (2018) Jonathan Galeotti et al. BRITISH JOURNAL OF HAEMATOLOGY
- Influence of IDH on FLT3-ITD status in newly diagnosed AML
- (2017) P Boddu et al. LEUKEMIA
- Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape
- (2017) P Silva et al. LEUKEMIA
- BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation
- (2017) Simon Raffel et al. NATURE
- AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
- (2017) Katharine Yen et al. Cancer Discovery
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
- (2016) K. H. Metzeler et al. BLOOD
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120
- (2016) K.C. Birendra et al. Clinical Lymphoma Myeloma & Leukemia
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metabolic consequences of oncogenic IDH mutations
- (2015) Seth J. Parker et al. PHARMACOLOGY & THERAPEUTICS
- TET proteins and the control of cytosine demethylation in cancer
- (2015) Laurianne Scourzic et al. Genome Medicine
- IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism
- (2014) A. R. Grassian et al. CANCER RESEARCH
- Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance
- (2014) Lev M. Kats et al. Cell Stem Cell
- Intravenous Vitamin C and Cancer
- (2014) Heidi Fritz et al. INTEGRATIVE CANCER THERAPIES
- DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
- (2014) A P Im et al. LEUKEMIA
- R-2-Hydroxyglutarate as the Key Effector of IDH Mutations Promoting Oncogenesis
- (2013) Dan Ye et al. CANCER CELL
- Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition
- (2013) C. Chen et al. GENES & DEVELOPMENT
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
- (2013) F. Wang et al. SCIENCE
- IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
- (2012) Masato Sasaki et al. NATURE
- The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
- (2011) Rasheduzzaman Chowdhury et al. EMBO REPORTS
- THE DIFFERENTIATION SYNDROME IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA: EXPERIENCE OF THE PETHEMA GROUP AND REVIEW OF THE LITERATURE.
- (2011) Pau Montesinos et al. Mediterranean Journal of Hematology and Infectious Diseases
- Acute Myeloid Leukemia WithIDH1orIDH2Mutation
- (2010) Keyur P. Patel et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status
- (2010) S. Schnittger et al. BLOOD
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
- (2010) Maria E. Figueroa et al. CANCER CELL
- Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes
- (2010) Vincenza Barresi et al. GENES CHROMOSOMES & CANCER
- Erratum: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2010) Lenny Dang et al. NATURE
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
- (2009) Elaine R. Mardis et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now